Skip to main content
. 2015 Mar 16;3(3):210–220. doi: 10.12998/wjcc.v3.i3.210

Figure 1.

Figure 1

Prospective studies evaluating a fixed 48-wk treatment using a standard dose of pegylated interferon and ribavirin in patients with hepatitis C genotype 4. SVR: Sustained viral response.